MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.61
-0.59
-1.59%
After Hours: 36.96 +0.35 +0.96% 16:14 07/29 EDT
OPEN
37.00
PREV CLOSE
37.20
HIGH
37.70
LOW
36.56
VOLUME
362.09K
TURNOVER
--
52 WEEK HIGH
71.25
52 WEEK LOW
30.41
MARKET CAP
5.14B
P/E (TTM)
-31.7162
1D
5D
1M
3M
1Y
5Y
Earnings Preview: Adaptive Biotechnologies (ADPT) Q2 Earnings Expected to Decline
Zacks.com · 1d ago
Microchip Announces Production Shipments of Industry's First NVMe and 24G SAS Tri-mode RAID and HBA Storage Adapters
Cloud service providers and server original equipment manufacturers (OEMs) designing storage platforms demand exceptional performance, flexibility and security for the next generation of data centers. Microchip Technology Inc. (Nasdaq: MCHP) today announce...
GlobeNewswire · 07/21 12:01
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
Exact Sciences, Vericel Corp, Home Depot, ExxonMobil and Discover Financial Services highlighted as Zacks Bull and Bear of the Day
Zacks · 07/19 13:54
Bull of the Day: Exact Sciences (EXAS)
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
Zacks · 07/19 09:20
Inflation Concerns Ruin First Week of Earnings Season
Inflation Concerns Ruin First Week of Earnings Season
Zacks · 07/17 13:15
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
Zacks.com · 07/15 14:36
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, ...
GlobeNewswire · 07/12 20:05
BRIEF-Vaccibody Enters Into Worldwide License Agreement With Adaptive Biotechnologies
reuters.com · 07/12 04:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADPT. Analyze the recent business situations of Adaptive Biotechnologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADPT stock price target is 55.20 with a high estimate of 60.00 and a low estimate of 47.00.
EPS
Institutional Holdings
Institutions: 313
Institutional Holdings: 114.36M
% Owned: 81.51%
Shares Outstanding: 140.31M
TypeInstitutionsShares
Increased
95
10.78M
New
46
2.07M
Decreased
76
7.61M
Sold Out
49
5.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Chad Robins
President
Julie Rubinstein
Co-Founder/Chief Scientific Officer
Harlan Robins
Chief Financial Officer
Chad Cohen
Chief Operating Officer
Mark Adams
Chief Human Resource Officer
Francis Lo
Senior Vice President/General Counsel
Stacy Taylor
Senior Vice President
Susan Bobulsky
Senior Vice President
Jyoti Palaniappan
Senior Vice President
Henning Thorsen
Other
Lance Baldo
Other
Sharon Benzeno
Lead Director/Independent Director
Peter Neupert
Independent Director
Kevin Conroy
Independent Director
Michelle Griffin
Independent Director
Robert Hershberg
Independent Director
Katey Owen
Independent Director
Michael Pellini
Independent Director
Leslie Trigg
No Data
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.